Figure 3.
Switching TNF inhibitors: ACR response 12 weeks after switching to adalimumab. Data from Bombardieri et al. [25]. ACR, American College of Rheumatology; TNF, tumour necrosis factor.
Rubbert-Roth and Finckh Arthritis Research & Therapy 2009 11(Suppl 1):S1 doi:10.1186/ar2666 |
